#CLAGM - Twitter Hashtag

almost 4 years ago

#Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with #Relapsed or #Refractory #AML in Phase 1 #ActimabA #CLAGM Combination Trial #ASH22 $ATNM https://t.co/U6EEapwpTx

0

2

0

1stOncology @1stOncology

almost 5 years ago

#ActiniumPharmaceuticalsInc Announces 72% #MRD Negativity Rate in the Recently Completed Phase 1 Study of #ActimabA in Combination with #CLAGM for Patients with #Relapsed or #Refractory #AML $ATNM https://t.co/K24Pqqc8r7

0

4

1

0

1stOncology @1stOncology

almost 5 years ago

#Actinium Announces Completion of Enrollment of #ActimabA #CLAGM Combination Trial in Patients with Relapsed or Refractory #AcuteMyeloidLeukemia Fit for #InductionTherapy $ATNM https://t.co/oNodbmBU08

0

1

0

Biotech @ej23ny

about 5 years ago

$ATNM very excited about this trial #ASH20 results: Phase 1/2 #Lintuzumab #Ac225 + #CLAGM in AML patients N=15 ORR 73% CR 67% #ASH21 Phase 1 Topline data N=18/21 Dose 1.0 μCi/kg/ 1.25 μCi/kg

0

11

2

0

Biotech @ej23ny

almost 6 years ago

$ATNM promising Phase 1 results #Lintuzumab #Ac225 + #CLAGM in patients with R/R AML N=15 Overall ORR 73% and 67% Complete Response $ATNM alpha particle platform is more advanced than $FUSN @TRIUMFInno @GlobalBC @GlobalBC @coleenchristie $NANOV https://t.co/LWprAnDoRu